The Spectranetics Corp (SPNC) 33.69 $SPNC
Shares of SPNC Up 13.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 4:50PM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 4 months, Spectranetics has returned 13.35% as of today's recent price of $33.63.
SPNC: 33.69 (-0.06)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Spectranetics Up 13.3% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Fri Feb 06, 11:16AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 4 months, Spectranetics has returned 13.26% as of today's recent price of $33.61.
SPNC: 33.69 (-0.06)
Spectranetics to Hold 2014 Fourth Quarter Financial Results Conference Call on February 19
GlobeNewswire - Thu Feb 05, 3:10PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2014 fourth quarter financial results after market close on Thursday, February 19, 2015. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 19 to discuss those results and to answer questions.
SPNC: 33.69 (-0.06)
NIRI's Rocky Mountain Chapter Presents: Regulation FD: A Fair Disclosure Update
Business Wire - Mon Feb 02, 8:00AM CST
Join the Rocky Mountain Chapter of the National Investor Relations Institute (NIRI) for February's feature presentation: "Regulation FD - A Fair Disclosure Update."
SPNC: 33.69 (-0.06), CROX: 10.62 (+0.04), QEP: 22.59 (+0.90)
Spectranetics Shares Up 14.7% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 30, 9:54AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 14.69% as of today's recent price of $34.03.
SPNC: 33.69 (-0.06)
Spectranetics Completes Acquisition of Stellarex(TM) Drug Coated Balloon Assets From Covidien
GlobeNewswire - Tue Jan 27, 10:09AM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced it has completed the acquisition of Covidien's Stellarex(TM) drug coated balloon angioplasty (DCB) platform. The transaction closed after the acquisition of Covidien by Medtronic.
SPNC: 33.69 (-0.06), MDT: 75.26 (+0.33)
Spectranetics Has Returned 16.9% Since SmarTrend Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 23, 9:32AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 16.86% as of today's recent price of $34.67.
SPNC: 33.69 (-0.06)
Emerging Diagnostic Imaging Market 2014-2020: Nuclear Imaging Systems, 3D imaging, Tactile imaging, Tomography, Emerging Diagnostic Biomarkers, Wearable diagnostic devices
M2 - Tue Jan 20, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/q69qj6/emerging) has announced the addition of the "Emerging Diagnostic Imaging Market - Devices, Global Industry Analysis, Growth, Trends, Forecast, Growth, Strategies and Opportunities - 2014-2020" report to their offering. Diagnostic Imaging Technologies provide imagery feedback on a patient's physical condition, which is then used to diagnose, monitor or treat medical conditions, thus playing an important role in improving public health of all age groups. X-ray based examinations are crucial in all medical settings and are utilised at every level. While practicing preventive as well as curative medicine, effective medical decisions require precise diagnostics, which technological advancements have significantly enhanced. These technological advancements initially started out with simple X-rays but have now revolutionized medical care in terms of diagnostics. Radiography, MRIs, CT scans, ultrasound, etc. have created a strong market in this field proving to be valuable and necessary investments are pouring in. Newer technologies have made diagnosis less invasive and more accurate, for example elastography tests the elasticity of organs, tactile sensing technology helps in minimum invasive surgery etc. This market is one of the few markets that have seen strong growth in both developed, and developing countries with significant investments specifically from hospitals, all over the globe. Medical Imaging and Technology Alliance (MITA), a branch of National Electrical Manufacturing Association (NEMA) is a collective representation of this market's R&D developers, manufacturers and innovators. Key Topics Covered: 1. Executive Summary 2. Emerging Diagnostic Imaging Technologies: Introduction 3. Market Overview 4. Drivers of Diagnostic Imaging Technologies 5. Restraints of Diagnostic Imaging Technologies 6. Opportunities of Diagnostic Imaging Technologies 7. Challenges of Diagnostic Imaging Technologies 8. Segmentation 9. Competitive Landscape 10. Geography Analysis 11. Company Profiling - Lumenis Ltd. - Biolase - Photomedex - IRIDEX corporation - Spectranetics Corporation For more information visit http://www.researchandmarkets.com/research/q69qj6/emerging
SPNC: 33.69 (-0.06), IRIX: 9.95 (unch), LMNS: 10.80 (+0.57)
Covidien's (COV) Stellarex DCB Gets CE Mark Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 12:30PM CST
Covidien plc's (COV) Stellarex DCB is designed to treat peripheral arterial disease (PAD) patients.
SPNC: 33.69 (-0.06), BCR: 175.38 (+0.50), MDT: 75.26 (+0.33), COV: 106.71 (-1.36)
15.6% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Thu Jan 08, 11:12AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 15.60% as of today's recent price of $34.30.
SPNC: 33.69 (-0.06)
Spectranetics to Present at the J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Mon Dec 29, 3:02PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the J.P. Morgan 33 Annual Healthcare Conference on January 14, 2015 in San Francisco.
SPNC: 33.69 (-0.06), JPM: 59.67 (+0.10)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
Spectranetics (SPNC) Worth Watching: Stock Rises 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:25AM CST
Spectranetics (SPNC) was a big mover last session, with shares rising nearly 8% on the day.
SPNC: 33.69 (-0.06), MVIS: 2.01 (+0.03), RSTI: 24.12 (+0.20), IPGP: 87.26 (+0.07)
Spectranetics Outlines Growth Opportunities at Analyst & Investor Meeting
GlobeNewswire - Thu Dec 04, 7:06AM CST
The Spectranetics Corporation (Nasdaq:SPNC) will provide an overview of several transformative growth drivers within its Vascular Intervention and Lead Management businesses during its Analyst & Investor meeting today in New York City. The company is also providing its financial outlook for 2015.
SPNC: 33.69 (-0.06)
Merger Arbitrage Mondays - December 1, 2014
Asif Suria - Seeking Alpha - Mon Dec 01, 9:46AM CST
Merger Activity decreased last week with three new mergers announced and four deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
KMI: 41.97 (+0.21), CIMT: 8.83 (+0.03), BMRN: 100.76 (+1.98), SGMS: 14.15 (+0.36), MDT: 75.26 (+0.33), RNR: 103.80 (-0.64), DDD: 32.81 (+0.40), COV: 106.71 (-1.36), KMP: 102.03 (+1.98), BYI: 83.27 (unch), GSK: 47.94 (+1.99), EPB: 44.10 (+1.05), SPNC: 33.69 (-0.06), RNA: 18.65 (unch), KMR: 104.71 (+3.81), PTP: 76.57 (-0.13), NVS: 102.20 (-0.17)
EU approves Medtronic/Covidien marriage
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:45AM CST
SPNC: 33.69 (-0.06), MDT: 75.26 (+0.33), COV: 106.71 (-1.36)
Shares of SPNC Up 13.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 4:50PM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 4 months, Spectranetics has returned 13.35% as of today's recent price of $33.63.
SPNC: 33.69 (-0.06)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Spectranetics Up 13.3% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Fri Feb 06, 11:16AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 4 months, Spectranetics has returned 13.26% as of today's recent price of $33.61.
SPNC: 33.69 (-0.06)
Spectranetics to Hold 2014 Fourth Quarter Financial Results Conference Call on February 19
GlobeNewswire - Thu Feb 05, 3:10PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2014 fourth quarter financial results after market close on Thursday, February 19, 2015. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 19 to discuss those results and to answer questions.
SPNC: 33.69 (-0.06)
NIRI's Rocky Mountain Chapter Presents: Regulation FD: A Fair Disclosure Update
Business Wire - Mon Feb 02, 8:00AM CST
Join the Rocky Mountain Chapter of the National Investor Relations Institute (NIRI) for February's feature presentation: "Regulation FD - A Fair Disclosure Update."
SPNC: 33.69 (-0.06), CROX: 10.62 (+0.04), QEP: 22.59 (+0.90)
Spectranetics Shares Up 14.7% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 30, 9:54AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 14.69% as of today's recent price of $34.03.
SPNC: 33.69 (-0.06)
Spectranetics Completes Acquisition of Stellarex(TM) Drug Coated Balloon Assets From Covidien
GlobeNewswire - Tue Jan 27, 10:09AM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced it has completed the acquisition of Covidien's Stellarex(TM) drug coated balloon angioplasty (DCB) platform. The transaction closed after the acquisition of Covidien by Medtronic.
SPNC: 33.69 (-0.06), MDT: 75.26 (+0.33)
Spectranetics Has Returned 16.9% Since SmarTrend Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 23, 9:32AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 16.86% as of today's recent price of $34.67.
SPNC: 33.69 (-0.06)
Emerging Diagnostic Imaging Market 2014-2020: Nuclear Imaging Systems, 3D imaging, Tactile imaging, Tomography, Emerging Diagnostic Biomarkers, Wearable diagnostic devices
M2 - Tue Jan 20, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/q69qj6/emerging) has announced the addition of the "Emerging Diagnostic Imaging Market - Devices, Global Industry Analysis, Growth, Trends, Forecast, Growth, Strategies and Opportunities - 2014-2020" report to their offering. Diagnostic Imaging Technologies provide imagery feedback on a patient's physical condition, which is then used to diagnose, monitor or treat medical conditions, thus playing an important role in improving public health of all age groups. X-ray based examinations are crucial in all medical settings and are utilised at every level. While practicing preventive as well as curative medicine, effective medical decisions require precise diagnostics, which technological advancements have significantly enhanced. These technological advancements initially started out with simple X-rays but have now revolutionized medical care in terms of diagnostics. Radiography, MRIs, CT scans, ultrasound, etc. have created a strong market in this field proving to be valuable and necessary investments are pouring in. Newer technologies have made diagnosis less invasive and more accurate, for example elastography tests the elasticity of organs, tactile sensing technology helps in minimum invasive surgery etc. This market is one of the few markets that have seen strong growth in both developed, and developing countries with significant investments specifically from hospitals, all over the globe. Medical Imaging and Technology Alliance (MITA), a branch of National Electrical Manufacturing Association (NEMA) is a collective representation of this market's R&D developers, manufacturers and innovators. Key Topics Covered: 1. Executive Summary 2. Emerging Diagnostic Imaging Technologies: Introduction 3. Market Overview 4. Drivers of Diagnostic Imaging Technologies 5. Restraints of Diagnostic Imaging Technologies 6. Opportunities of Diagnostic Imaging Technologies 7. Challenges of Diagnostic Imaging Technologies 8. Segmentation 9. Competitive Landscape 10. Geography Analysis 11. Company Profiling - Lumenis Ltd. - Biolase - Photomedex - IRIDEX corporation - Spectranetics Corporation For more information visit http://www.researchandmarkets.com/research/q69qj6/emerging
SPNC: 33.69 (-0.06), IRIX: 9.95 (unch), LMNS: 10.80 (+0.57)
Covidien's (COV) Stellarex DCB Gets CE Mark Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 12:30PM CST
Covidien plc's (COV) Stellarex DCB is designed to treat peripheral arterial disease (PAD) patients.
SPNC: 33.69 (-0.06), BCR: 175.38 (+0.50), MDT: 75.26 (+0.33), COV: 106.71 (-1.36)
15.6% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Thu Jan 08, 11:12AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 24th, 2014 at $29.67. In approximately 3 months, Spectranetics has returned 15.60% as of today's recent price of $34.30.
SPNC: 33.69 (-0.06)
Spectranetics to Present at the J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Mon Dec 29, 3:02PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the J.P. Morgan 33 Annual Healthcare Conference on January 14, 2015 in San Francisco.
SPNC: 33.69 (-0.06), JPM: 59.67 (+0.10)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
Spectranetics (SPNC) Worth Watching: Stock Rises 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:25AM CST
Spectranetics (SPNC) was a big mover last session, with shares rising nearly 8% on the day.
SPNC: 33.69 (-0.06), MVIS: 2.01 (+0.03), RSTI: 24.12 (+0.20), IPGP: 87.26 (+0.07)
Spectranetics Outlines Growth Opportunities at Analyst & Investor Meeting
GlobeNewswire - Thu Dec 04, 7:06AM CST
The Spectranetics Corporation (Nasdaq:SPNC) will provide an overview of several transformative growth drivers within its Vascular Intervention and Lead Management businesses during its Analyst & Investor meeting today in New York City. The company is also providing its financial outlook for 2015.
SPNC: 33.69 (-0.06)
Merger Arbitrage Mondays - December 1, 2014
Asif Suria - Seeking Alpha - Mon Dec 01, 9:46AM CST
Merger Activity decreased last week with three new mergers announced and four deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
KMI: 41.97 (+0.21), CIMT: 8.83 (+0.03), BMRN: 100.76 (+1.98), SGMS: 14.15 (+0.36), MDT: 75.26 (+0.33), RNR: 103.80 (-0.64), DDD: 32.81 (+0.40), COV: 106.71 (-1.36), KMP: 102.03 (+1.98), BYI: 83.27 (unch), GSK: 47.94 (+1.99), EPB: 44.10 (+1.05), SPNC: 33.69 (-0.06), RNA: 18.65 (unch), KMR: 104.71 (+3.81), PTP: 76.57 (-0.13), NVS: 102.20 (-0.17)
EU approves Medtronic/Covidien marriage
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:45AM CST
SPNC: 33.69 (-0.06), MDT: 75.26 (+0.33), COV: 106.71 (-1.36)
